Contraindicated (1)bortezomib will improve the degree or outcome of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Potent or moderate CYP2C19 inhibitors may perhaps maximize mavacamten systemic exposure, leading to heart failure due to systolic dysfunction. Lab and/or health care assessments (including entire blood rely) should be accomplished if you https://paulw111jvf3.salesmanwiki.com/user